Johnson & Johnson seeks DGCI nod for EUA of its single-dose COVID vaccine in India
Johnson & Johnson's vaccine is a single-dose jab, whereas the three vaccines cleared by India so far are of double doses.
FollowMultinational pharma giant Johnson & Johnson on Friday applied to India's drug regulator seeking the Emergency Use Authorization (EUA) of its Covid-19 single-dose vaccine in India.
A Johnson & Johnson India spokesperson in a statement said, on August 5, Johnson & Johnson Pvt Ltd had applied for emergency use of its Covid-19 single-dose vaccine to the Indian government .
It is an important milestone that paves the way for bringing the company's single-dose Covid-19 vaccine to the people of India, and the rest of the world, through a collaboration with Biological E Limited.
The statement added that Biological E will be an important part of our global supply chain network, helping to supply our Johnson & Johnson Covid-19 vaccine through the extensive collaborations and partnerships we have with governments, health authorities and organisations such as Gavi and the COVAX Facility.
The J&J vaccine can be stored for up to three months in a temperature between 2 and 8 degrees Celsius.
Johnson & Johnson's vaccine is a single-dose jab, whereas the three vaccines cleared by India so far are of double doses.
India has so far approved four vaccines - AstraZeneca's Covishield, Bharati Biotech's Covaxin, Russian Gamaleya Institute's Sputnik V and Moderna's vaccine.
India logged 44,643 new coronavirus cases on Thursday taking the total tally to 3,18,56,757, while the active cases soared for a third consecutive day, according to the Health Ministry data. The fatalities  toll climbed to 4,26,754 with 464 fresh deaths.
NOTE: Asianet News humbly requests everyone to wear masks, sanitize, maintain social distancing and get vaccinated as soon as eligible. Together we can and will break the chain #ANCares #IndiaFightsCorona
